Rafi Sakhi1, Amira Assaf1, Dominic A M J Theuns1, Judith M A Verhagen2, Tamas Szili-Torok1, Jolien W Roos-Hesselink1, Sing-Chien Yap3. 1. Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 2. Department of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 3. Department of Cardiology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands, s.c.yap@erasmusmc.nl.
Abstract
INTRODUCTION: There is limited data on the experience with insertable cardiac monitors (ICMs) in patients with Brugada syndrome. OBJECTIVE: To evaluate the outcome of ICM in symptomatic patients with Brugada syndrome who are at suspected low risk of sudden cardiac death (SCD). METHODS: We conducted a prospective single-center cohort study including all symptomatic patients with Brugada syndrome who received an ICM (Reveal LINQ) between July 2014 and October 2019. The main indication for monitoring was to exclude ventricular arrhythmias as the cause of symptoms and to establish a symptom-rhythm relationship. RESULTS: A total of 20 patients (mean age, 39 ± 12 years; 55% male) received an ICM during the study period. Nine patients (45%) had a history of syncope (presumed nonarrhythmogenic), and 5 patients had a recent syncope (<6 months). During a median follow-up of 32 months (interquartile range, 11-36 months), 3 patients (15%) experienced an episode of nonsustained ventricular arrhythmia. No patient died suddenly or experienced a sustained ventricular arrhythmia, and no patient had a recurrence of syncope. Overall, 17 patients (85%) experienced symptoms during follow-up, of whom 10 patients had an ICM-detected arrhythmia. In 4 patients (20%), the ICM-detected arrhythmia was an actionable event. ICM-guided management included antiarrhythmic drug therapy for symptomatic ectopic beats (n = 3), pulmonary vein isolation, and oral anticoagulation for atrial fibrillation (n = 1), electrophysiological study for risk stratification (n = 1), and pacemaker implantation for atrioventricular block (n = 1). CONCLUSIONS: An ICM can be used to exclude ventricular arrhythmias in symptomatic patients with Brugada syndrome at low risk of SCD. Furthermore, an ICM-detected arrhythmia changed clinical management in 20% of patients.
INTRODUCTION: There is limited data on the experience with insertable cardiac monitors (ICMs) in patients with Brugada syndrome. OBJECTIVE: To evaluate the outcome of ICM in symptomatic patients with Brugada syndrome who are at suspected low risk of sudden cardiac death (SCD). METHODS: We conducted a prospective single-center cohort study including all symptomatic patients with Brugada syndrome who received an ICM (Reveal LINQ) between July 2014 and October 2019. The main indication for monitoring was to exclude ventricular arrhythmias as the cause of symptoms and to establish a symptom-rhythm relationship. RESULTS: A total of 20 patients (mean age, 39 ± 12 years; 55% male) received an ICM during the study period. Nine patients (45%) had a history of syncope (presumed nonarrhythmogenic), and 5 patients had a recent syncope (<6 months). During a median follow-up of 32 months (interquartile range, 11-36 months), 3 patients (15%) experienced an episode of nonsustained ventricular arrhythmia. No patient died suddenly or experienced a sustained ventricular arrhythmia, and no patient had a recurrence of syncope. Overall, 17 patients (85%) experienced symptoms during follow-up, of whom 10 patients had an ICM-detected arrhythmia. In 4 patients (20%), the ICM-detected arrhythmia was an actionable event. ICM-guided management included antiarrhythmic drug therapy for symptomatic ectopic beats (n = 3), pulmonary vein isolation, and oral anticoagulation for atrial fibrillation (n = 1), electrophysiological study for risk stratification (n = 1), and pacemaker implantation for atrioventricular block (n = 1). CONCLUSIONS: An ICM can be used to exclude ventricular arrhythmias in symptomatic patients with Brugada syndrome at low risk of SCD. Furthermore, an ICM-detected arrhythmia changed clinical management in 20% of patients.
Authors: Silvia G Priori; Arthur A Wilde; Minoru Horie; Yongkeun Cho; Elijah R Behr; Charles Berul; Nico Blom; Josep Brugada; Chern-En Chiang; Heikki Huikuri; Prince Kannankeril; Andrew Krahn; Antoine Leenhardt; Arthur Moss; Peter J Schwartz; Wataru Shimizu; Gordon Tomaselli; Cynthia Tracy Journal: Heart Rhythm Date: 2013-08-30 Impact factor: 6.343
Authors: Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page Journal: Circulation Date: 2018-09-25 Impact factor: 29.690
Authors: V Probst; C Veltmann; L Eckardt; P G Meregalli; F Gaita; H L Tan; D Babuty; F Sacher; C Giustetto; E Schulze-Bahr; M Borggrefe; M Haissaguerre; P Mabo; H Le Marec; C Wolpert; A A M Wilde Journal: Circulation Date: 2010-01-25 Impact factor: 29.690
Authors: Juan Sieira; Giulio Conte; Giuseppe Ciconte; Gian-Battista Chierchia; Ruben Casado-Arroyo; Giannis Baltogiannis; Giacomo Di Giovanni; Yukio Saitoh; Justo Juliá; Giacomo Mugnai; Mark La Meir; Francis Wellens; Jens Czapla; Gudrun Pappaert; Carlo de Asmundis; Pedro Brugada Journal: Eur Heart J Date: 2017-06-07 Impact factor: 29.983
Authors: Jakub Sroubek; Vincent Probst; Andrea Mazzanti; Pietro Delise; Jesus Castro Hevia; Kimie Ohkubo; Alessandro Zorzi; Jean Champagne; Anna Kostopoulou; Xiaoyan Yin; Carlo Napolitano; David J Milan; Arthur Wilde; Frederic Sacher; Martin Borggrefe; Patrick T Ellinor; George Theodorakis; Isabelle Nault; Domenico Corrado; Ichiro Watanabe; Charles Antzelevitch; Giuseppe Allocca; Silvia G Priori; Steven A Lubitz Journal: Circulation Date: 2016-01-21 Impact factor: 29.690